Medindia

X

Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013

Saturday, November 21, 2009 General News J E 4
Advertisement


NEW YORK, Nov. 20 Reportlinker.com announces that a new market research report is available in its catalogue.

Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013

http://www.reportlinker.com/p0164998/Oncology-Roadmap-Brand-Spending-Benchmarks-and-Market-Forecast-to-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

Comprehensive Forecasts and Detailed Budget Benchmarks new report, "Oncology Roadmap," explores the fiercely competitive oncology market in a way that no other available forecast can match.

Our experienced analysts have reviewed thousands of historical and forecasted data points to provide the most comprehensive oncology market outlook ever.

At the same time, brand budget benchmarks reveal spending in key areas throughout development and launch.

Uncover Oncology Threats and Opportunities

Equip your teams with the most comprehensive forecast of the oncology marketplace -- from today's stalwarts to tomorrow's blockbusters.

Product Breakdown

112 Anti-cancer drugs in all major classes

15 Adjuncts

Product Profile Components

-Product history

-Competitive and strategic positioning

-Market growth opportunities

-Sales history and projections

-Drug's materiality to company

Budget Brand Resources for Development and Launch

Track real brand spending from the pre-clinical period through the first year on the market

Brand Spending Benchmarks

-Advertising and promotion

-Medical affairs

-Decision support (market research)

-Market access

Summary

Brand Spending Benchmarks

Average brand spending by budget category:

- Advertising and promotion

- Medical affairs

- Decision support (market research)

- Market access

Average brand spending by development stage:

- Pre-Clinical to phase 2

- Phase 3a

- Phase 3b

- First year on the market

Product Profiles by Class

Brand Information

- Brand and generic name

- Drug class

- Delivery mechanism

- Line of treatment

Sales Data

- Historical/current sales

- Forecasted sales

Approved Indications

- Current Product Development Phases

- Competitive and Strategic Positioning

- Market Opportunities and Brand Growth

- Patent, Generic and Litigation Information

Oncology Indication Analysis

- Current sales, major drugs and important companies

- Forecasted sales and assessment of future drugs and market players

- Pipeline development status

- Major market events, changes in treatments, patent expirations, etc.

Companies' Oncology Portfolios

- Current sales, major drugs and important companies

- Forecasted sales and assessment of future drugs and market players

- Pipeline development status

Companies mentioned

Amgen AstraZeneca Bristol-Myers Squibb Celgene Eli Lilly GlaxoSmithKline Johnson & Johnson Merck Novartis Pfizer Roche and Genentech Sanofi-Aventis Schering-Plough

To order this report:

Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013

http://www.reportlinker.com/p0164998/Oncology-Roadmap-Brand-Spending-Benchmarks-and-Market-Forecast-to-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

More market research reports here!

Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Case Studies Offer Inside Look at Effective Ways t...
S
LightSource Poll - Empire State Edition by KJT Gro...